Pharmaceutical Business Review
Drug Discovery & Development
Anonymous User | Login

Novartis, Wellcome Trust To Develop Vaccine For Typhoid Fever

Published: 04-Jun-2009

E5.15 million granted to fund preclinical development and phase I and II clinicla trial studies for the vaccine

Novartis has announced that the Novartis Vaccines Institute for Global Health has been awarded a grant from the Wellcome Trust to develop a bivalent vaccine for typhoid fever.

The E5.15 million grant will fund preclinical development and phase I and II studies for a vaccine that protects against both S. Typhi and S. Paratyphi A. The currently available vaccines for S. Typhi do not protect infants and young children. S. Paratyphi A is a growing problem causing 25-50% of all typhoid cases.

Dr. Daniel Vasella, Chairman and CEO of Novartis, said: The bivalent vaccine being developed by NVGH will use a novel approach to increase efficacy and address the needs of patients that other vaccines have not. This will ultimately have the potential to eradicate this disease.

Mail sent successfully

Tell your friend about this article


Please enter a valid email address

Please enter your name

Please enter the mail body


Your Name: *
Your Email: *
Friend's Email: *
Email Body: *
 

Suppliers To This Sector

Browse A-Z

# A B C D E F G H I J K L M N O P Q R S T U V W X Y Z

ADAPT Localization

The Translation and Localization Specialists ...

Anoto

Providing Unique Technology for Digital Pen and Paper ...

Aptuit

Drug Discovery and Development ...

Bachem

Process Development and Manufacturing of Peptides and Complex Organic Molecules as APIs ...

BaseCon

IT Pharma Solutions ...

Bioceros

Pre-Clinical Development of Monoclonal Antibodies and Generation of GMP-Ready Proteins ...

White Papers

Browse A-Z

# A B C D E F G H I J K L M N O P Q R S T U V W X Y Z

CaseBase Management

BaseCon was established in 1999 to support the pharmaceutical sector with innovative IT so ...

SafetyBase Interchange

BaseCon was established in 1999 to support the pharmaceutical sector with innovative IT so ...

ClinicalBase Trial

BaseCon was established in 1999 to support the pharmaceutical sector with innovative IT so ...

Reliable Prediction of White Plasma Levels

Our kinetics & metabolism experts can help you select and further develop your candidate d ...

Kinetics and Metabolism

Our kinetics & metabolism experts can help you select and further develop your candidate d ...

Drug Safety Evaluation

Our kinetics & metabolism experts can help you select and further develop your candidate d ...

Related Companies

GlaxoSmithKline plc

GlaxoSmithKline plc (GSK) is a is a United Kingdom-based pharmaceutical, biological, a ...

Merck KGaA

Merck KGaA (Merck) is a Germany-based company engaged in the manufacturing and distribu ...

Wyeth

Wyeth is engaged in developing and providing pharmaceuticals and healthcare products fo ...

Bristol-Myers Squibb Company

Bristol-Myers Squibb Company is engaged in the discovery, development, licensing, manuf ...

Johnson & Johnson

Johnson & Johnson (J&J) is engaged in the manufacture and sales of broad range of healt ...

Suppliers Product News

Organisations Throwing Mobile Technology at Problems With Little Consideration of Actual User and Business Needs, Quocirca

Survey reveals detrimental impact on organisational effectiveness and IT expenditure in healthcare and finance across the UK, France, Germany and the US.

Digital Pen and Paper Technology Helps Accelerate Clinical Trials

Digital pen and paper technology captures handwritten clinical data electronically, quickly and securely to save time and cost in drug discovery process.

Aptuit Outlines 2010 Business Priorities at 28th Annual J.P. Morgan Healthcare Conference

Aptuit, Inc., a contract development and manufacturing company, today will provide an update on 2010 business priorities and discuss its integrated service offerings at the 28th Annual J.P. Morgan Healthcare Conference in San Francisco.

Aptuit Publishes Study which Demonstrates the Value of Early Insights into the Characterisation of Drug Compounds

New research on the solid-state characterisation of finasteride clearly outlines a systematic approach to characterising and monitoring active pharmaceutical ingredients

Aptuit Launches Program to Accelerate Early Stage Drug Development

Aptuit INDiGO™ accelerates drug development from pre-clinical candidate selection to regulatory filing on a fixed timeline and price

mondoBIOTECH and Bachem Agree Long-Term Cooperation on the Development of Peptides to Fight Rare Diseases

mondoBIOTECH and Bachem on 24 September announced the conclusion of a longterm cooperation.

Free Newsletter Sign-up

Sign up, and we will send you a free Pharmaceutical report on “ Combination Products – Evolution of the Medical Equipment Industry” from GlobalData worth $750

Please enter a valid email address